



GIG
CYMRU
NHS
WALES

Iechyd Cyhoeddus
Cymru
Public Health
Wales

Name of Meeting
Board
Date of Meeting
27 January 2022
Agenda item:
6b

Public Health Wales Corporate Risk Register

Executive lead:	Rhiannon Beaumont-Wood, Executive Director of Quality, Nursing and Allied Health Professionals
Author:	John Lawson, Chief Risk Officer

Approval/Scrutiny route:	Rhiannon Beaumont-Wood, Executive Director of Quality, Nursing and Allied Health Professionals
---------------------------------	--

Purpose
Receive the Corporate Risk Registers for the purpose of scrutiny, challenge and assurance.

Recommendation:				
APPROVE <input type="checkbox"/>	CONSIDER <input checked="" type="checkbox"/>	RECOMMEND <input type="checkbox"/>	ADOPT <input type="checkbox"/>	ASSURANCE <input checked="" type="checkbox"/>

The Board is asked to: <ul style="list-style-type: none"> • Receive the Corporate Risk Register for the purposes of scrutiny and challenge.

Link to Public Health Wales [Strategic Plan](#)

Public Health Wales has an agreed strategic plan, which has identified seven strategic priorities.

This report contributes to all Strategic Priorities

Strategic Priority	Choose an item.
---------------------------	-----------------

Strategic Priority	Choose an item.
---------------------------	-----------------

Summary impact analysis

Equality and Health Impact Assessment	No decision is required.
Risk and Assurance	This submission is the Corporate Risk Register.
Health and Care Standards	This report supports and/or takes into account the Health and Care Standards for NHS Wales Quality Themes Governance, Leadership and Accountability
Financial implications	The financial implications of failing to manage corporate risk effectively are significant, both in terms of the potential for loss and also the failure to capitalise on opportunities.
People implications	No people implications.

1. Purpose / situation

This paper introduces the organisations Corporate Risk Register, highlighting any areas of concern that may require further discussion. This paper must be read in conjunction with the Corporate Risk Register.

All Committees consider the Corporate Risk Register and the relevant risks specific to the Committee at each Committee meeting.

The CRR is provided to the Board twice a year to offer assurance over and above the role of the Committees and Business Executive Team.

2. Corporate Risk Register

Summary

The Corporate Risk Register currently represents the 8 operational risks that are deemed to require management at Executive level.

A summary of the Corporate Risks can be found in Appendix A.

The Corporate Risk Register was extensively revised in 2021 by the Business Executive Team (BET) when it was decided that there was no longer any need to show Covid-19 specific risks separately.

A further detailed review was carried out by BET in December 2021.

There are 6 risks with a residual risk rating of extreme, and a further two with a risk rating of high.

Actions and updates

Two risks (201 and 205) have actions which either have no target dates, or in which the target date has passed.

Five risks have been updated in the last month, with the other three being updated in late November.

A summary of actions and updates can be found in Appendix B.

Risk movements this period

Risks added since the previous month

- None

Risks to be considered for escalation (Separate escalation form required)

- None

Risks to be considered for de-escalation or removal

- None

Risks increasing in severity score since the previous month

- None

Risks decreasing in severity score since the previous month

- None

Risks requiring approval to change action target dates

- The target date for Risk 203 was amended by BET in December 2021 from 30/10/2021 to 31/03/2022

Further work recommended or ongoing

- None

3. Well-being of Future Generations (Wales) Act 2015

No decision required.

4. Recommendation

The Board is asked to:

- **Receive** the Corporate Risk Register for the purposes of scrutiny and challenge.

Appendix A – Summary of Corporate Risks by rating, decision & Executive lead

Total number of Corporate Risks		8
No. of Risks by severity (residual score)	Extreme	6
	High	2
	Moderate	0
	Low	0
No. of risks by Decision	Terminate	0
	Transfer	0
	Treat	8
	Tolerate	0
No. of risks by Exec Lead		
	Chief Executive	0
	Executive Director Finance	0
	Executive Director HPSS	2
	Executive Director QNAHPs	1
	Director of POD	3
	Transition Director of H&W	0
	Director of Knowledge	1
	Director of WHO Collaborating Centre	0
	Director of Improvement Cymru	0
	Board Secretary	1
Not assigned	0	
No. of risks with overdue actions (see 'Key points')		2

Appendix B – Summary of Corporate Risks by Action and Update status

Ref	Headline	Exec Owner	Number of open actions	Actions status	Last updated	Comments
201	Fail to manage organisational change	NL	1		Dec 21	
202	Fail to adequately prepare for the forthcoming Public Inquiry	HB	4		Jan 22	
203	Failure in service delivery in Diabetic Eye Screening	MK	1		Nov 21	
204	Fail to exploit data	IB	1		Nov 21	
205	Fail to recruit and retain workforce	NL	3		Dec 21	
206	Performance will not be aligned to the organisations strategy	NL	2		Dec 21	
207	Fail to implement an effective quality management system which reflects the requirements of the Quality and Engagement Act.	RBW	5		Jan 22	
208	Failure to recruit and retain sufficient medical microbiologists	MK	4		Nov 21	

Numbering convention.

Since the review of Corporate risks in 2021, for clarity all risks are now numbered in the series 2xx.

Action status

	Actions overdue or no actions present
	All actions on track or risk marked as Tolerate

Update status

	No update provided in previous 3 months
	No update provided in the past month
	Risk updated within the past month